Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes

• Published in: Liver international Vol. 41; no. 11; pp. 2534 - 2546
• Main Authors: Steinman, Jonathan B., Salomao, Marcela A., Pajvani, Utpal B.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc 01-11-2021
• Subjects: Clinical outcomes; Clinical trials; Cysteamine; developmental signaling; Fatty liver; Fibrosis; Inflammation; Liver diseases; liver zonation; non-alcoholic steatohepatitis (NASH); non‐alcoholic fatty liver disease (NAFLD); Nuclear receptors; Pathogenesis; Pioglitazone; precision medicine; Steatosis; Wnt protein; Zonation
• ISSN: 1478-3223; 1478-3231
• DOI: 10.1111/liv.15025

Non‐alcoholic fatty liver disease (NAFLD) exists as a spectrum ranging from simple steatosis to histologically defined hepatocyte injury and inflammatory changes that define steatohepatitis (NASH), and increase risk for fibrosis. Although zonal differences in NASH have not been systematically studied, periportal involvement has been associated with worse metabolic outcomes and more hepatic fibrosis as compared to pericentral disease. These data suggest that hepatic zonation of disease may influence the diversity of clinical presentations. Similarly, several randomized clinical trials suggest a differential response based on zonation of disease, with preferential effects on periportal (cysteamine) or pericentral disease (obeticholic acid, pioglitazone). Intriguingly, morphogenic pathways known to affect zonal development and maintenance – WNT/β‐Catenin, Hedgehog, HIPPO/Yap/TAZ and Notch – have been implicated in NASH pathogenesis, and nuclear hormone receptors downstream of potential NASH therapeutics show zonal preferences. In this review, we summarize these data and propose that patient‐specific activation of these pathways may explain the variability in clinical presentation, and the zone‐specific response observed in clinical trials.